Q2
– Conditional early approval application submitted to Min. of Health, Labour and Welfare in Japan
Q3
– Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
